EP2710130B1 - Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren - Google Patents

Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren Download PDF

Info

Publication number
EP2710130B1
EP2710130B1 EP12727326.6A EP12727326A EP2710130B1 EP 2710130 B1 EP2710130 B1 EP 2710130B1 EP 12727326 A EP12727326 A EP 12727326A EP 2710130 B1 EP2710130 B1 EP 2710130B1
Authority
EP
European Patent Office
Prior art keywords
promoter
repressor
expression
transcriptional
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12727326.6A
Other languages
English (en)
French (fr)
Other versions
EP2710130A1 (de
Inventor
Francisco MARTÍN MOLINA
Karim BENABDELLAH EL KHLANJI
Marién COBO PULIDO
Miguel GARCÍA TOSCANO
Pilar MUÑOZ FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Salud Carlos III
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
Instituto de Salud Carlos III
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Salud Carlos III, Fundacion Publica Andaluza Progreso y Salud filed Critical Instituto de Salud Carlos III
Priority to EP12727326.6A priority Critical patent/EP2710130B1/de
Publication of EP2710130A1 publication Critical patent/EP2710130A1/de
Application granted granted Critical
Publication of EP2710130B1 publication Critical patent/EP2710130B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB

Definitions

  • the invention relates to the field of gene expression and, more in particular, to reagents and methods which allow regulated expression of a gene of interest in a cell without the requirements of cell cloning and/or antibiotic selection.
  • Inducible gene expression systems based on antibiotics or hormones are a potent research tools and are constantly developed for their use in basic research and/or clinical application.
  • the rtTA-regulatable system is the most widely exploited tool for controlling gene expression.
  • This system described for the first time in WO9429442 , is based on a chimeric transcription factor consisting on the fusion of the bacterial tet repressor (TetR) with the activating domain of the viral protein 16 (VP-16), resulting in a tetracycline responsive transactivator (tTA).
  • rtTA reverse tetracycline controlled trans -activator
  • the rtTA -based system requires the addition of tetracycline to activate transcription (TET-ON system) by allowing the binding of the rtTA to the TetO-CMV promoter.
  • TET-ON system tetracycline to activate transcription
  • Several improvement of the rtTA have been done that improve inducibility and reduce background.
  • all these tetracycline-inducible systems require a tetracycline-dependant-transactivator to activate the regulated promoter.
  • transactivator for transcriptional activity has several undesired consequences, in particular, the promoter endogenous expression pattern may be altered due to the activation of the promoters of the regulated promoters, the possible activation of cellular genes due to the binding of the transactivator to pseudo-TetO sites and the toxicity caused by the presence of a transactivating domain makes these proteins very toxic. In fact, several studies have demonstrated that the rtTA-based systems can give rise to data misinterpretation due to the toxicity of the transactivator.
  • the invention relates to a lentiviral vector comprising a polynucleotide, wherein the polynucleotide comprises
  • the invention relates to a lentiviral particle or host cell comprising a lentiviral vector of the invention.
  • the invention in another aspect, relates to a composition or kit-of-parts comprising the lentiviral vector of the invention and a ligand of the transcriptional repressor which, when bound to the repressor, results in the inactive repressor which is no longer capable of binding to its binding site in the transcriptional regulatory sequence.
  • the invention relates to an in vitro method for regulating the expression of a nucleic acid sequence of interest comprising the steps of
  • the invention relates to a lentiviral vector, a host cell or a lentiviral particle according to the invention for use in medicine.
  • the invention relates to a lentiviral vector, a host cell or a lentiviral particle according to the invention for use in the treatment of a disease which requires the expression of the polynucleotide under operative control of the transcriptional regulatory sequence.
  • Fig 1 Two vector system for efficient doxycycline regulation of transgenes using the TetR repressor.
  • A Maps of the two lentiviral vectors required for doxycycline-dependant transgene regulation.
  • the TetR repressor is expressed through the constitutive SFFV promoter, highly active in most cell types, including hematopoietic cells.
  • the second lentiviral vector contain the doxycycline-responsive CMV-TetO promoter ( Yao et al 1998, Hum Gene Ther. 9: 1939-50 ) driving the expression of eGFP.
  • Fig.2 GFP induction level using binary lentiviral vectors A) 293T cells were stably transduced with increasing amount of STetR lentiviral vector. Different TetR-expressing 293T cell lines were generated each harbouring an average of 0.2, 0.8, 2, 4 and 9 copies per cell (c.c.) (indicated on the top of Figure A). Each of these TetR-expressing 293T cell lines where later transduced with increasing amount of CTetOE vectors (average of 0.5, 3, 6 and 10 c.c) (indicated on the left of figure A). Plots show eGFP expression of the different cell lines in the absence (-Dox) or presence (+Dox) of 1 ⁇ g of doxycycline. B.
  • Fig 3 Easy generation of highly responsive cell lines with the all-in-one doxycline-controlable lentiviral vector CEST.
  • the different cell lines were incubated in the absence of doxycycline (-Dox), and with 0.001 ⁇ g/ml, 0.01 ⁇ g /ml and 0.1 ⁇ g /ml as indicated on the top.
  • the leaking in the absence of doxycycline decrease as the vector copy number increase (left graphs from top to bottom).
  • C Fold induction (left panels) and leaking (right panels) in 293T (top panels) and human mesenchymal stem cells (hMSC) (bottom panles) transduced with increasing MOIs of the CEST vector.
  • the average CEST vector copies per genome of the different cell lines analyzed are indicated at the bottom of the graphs. The best regulation in terms of higher inducibility and lower leaking is achieved in the cells that contain the highest number of CEST vector integrated.
  • FIG. 4 Doxycycline-responsive human mesenchymal stem cells (hMSCs) maintain the main properties of parental hMSCs.
  • hMSCs Doxycycline-responsive human mesenchymal stem cells
  • FIG. 5 Development of the CEETn.
  • the CEETn (bottom) was constructed using the CEST vector (top) as backbone.
  • FIG. 6 The CEETn efficiently modulate transgene expression at low copy number. Otice the low leaking (no transgene expression in absence of doxycicline) and good inducibility after doxycicline addition in mouse (left panels) and human (middle pplots) mesenchymal stem cells (MSC) as well as in 293T cells.
  • MSC mesenchymal stem cells
  • FIG. 7 The CEETn lentiviral vector modulate transgene expression in bulk populations of human embryonic stem cells (hESCs).
  • hESCs human embryonic stem cells
  • the invention relates to a lentiviral vector comprising a polynucleotide, wherein the polynucleotide comprises
  • nucleic acid molecule As used herein, the terms "polynucleotide” or “nucleic acid molecule” are intended to include DNA molecules ⁇ e.g., cDNA or genomic DNA) and RNA molecules ⁇ e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • the nucleic acid may be synthesized using oligonucleotide analogs or derivatives ⁇ e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides may be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.
  • the first component of the all-in-one vector according to the invention is a transcriptional regulatory sequence.
  • transcriptional regulatory sequence refers to a nucleic acid sequence which is capable of governing the expression of another nucleic acid sequence operatively linked thereto, such as a gene of interest.
  • the transcription control sequence preferably, is a DNA sequence.
  • the transcriptional control sequence comprises a first promoter and at least one binding site for a transcriptional repressor wherein said first promoter and said binding site for a transcriptional repressor are arranged so that the binding of the transcriptional repressor to said binding site inhibits the transcriptional activity of the promoter.
  • promoter refers to a DNA sequence that determines the site of transcription initiation for an RNA polymerase.
  • Promoter sequences comprise motifs which are recognized and bound by polypeptides, i.e. transcription factors.
  • the said transcription factors shall upon binding recruit RNA polymerases II, preferably, RNA polymerase I, II or III, more preferably, RNA polymerase II or III, and most preferably, RNA polymerase II. Thereby will be initiated the expression of a nucleic acid operatively linked to the transcription control sequence.
  • expression as meant herein may comprise transcription of DNA sequences into RNA polynucleotides (as suitable for, e.g., anti-sense approaches, RNAi approaches or ribozyme approaches) or may comprise transcription of DNA sequences into RNA polynucleotides followed by translation of the said RNA polynucleotides into polypeptides (as suitable for, e.g., gene expression and recombinant polypeptide production approaches).
  • the transcription control sequence may be located immediately adjacent to the nucleic acid to be expressed, i.e. physically linked to the said nucleic acid at its 5 'end. Alternatively, it may be located in physical proximity. In the latter case, however, the sequence must be located so as to allow functional interaction with the nucleic acid to be expressed.
  • the first promoter is the cytomegalovirus (CMV) immediate early promoter.
  • the first promoter is a promoter functional in mammalian cells.
  • the first promoter is a high-level constitutive promoter. Examples of such promoters not part of the invention, include, without limitation, the retroviral Rous sarcoma virus (RSN) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985 )], the SN40 promoter, the dihydrofolate reductase promoter, the beta -actin promoter, the beta -active promoter linked to the enhancer derived from the cytomegalovirus (CMN) immediate early (IE) promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter [Invitrogen].
  • Inducible promoters are regulated by exogenously supplied compounds, including, the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system [ WO 98/10088 ]; the ecdysone insect promoter [ No et al, Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996 )], the tetracycline-repressible system [ Gossen et al, Proc. Natl. Acad. Sci.
  • inducible promoters are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • the native promoter for the transgene will be used.
  • the native promoter may be preferred when it is desired that expression of the gene should mimic the native expression.
  • the native promoter may be used when expression of the gene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli.
  • other native expression control elements such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.
  • the transgene product or other desirable product to be expressed is operably linked to a tissue-specific promoter. For instance, if expression in skeletal muscle is desired, a promoter active in muscle should be used.
  • tissue-specific are known for liver [albumin, Miyatake et al. J Virol, 71:5124-32 (1997 ); hepatitis B virus core promoter, Sandig et al, Gene Ther., 3:1002-9 (1996 ); and alpha-fetoprotein (AFP), Arbuthnot et al, Hum.
  • a promoter referred to herein can be derived from the Cytomegalovirus (CMV) minimal promoter and, more preferably, from human CMV (hCMV) such as the hCMV immediate early promoter derived minimal promoter as described in, e.g., Gossen and Bujard (Proc. Natl. Acad. Sci. USA, 1992, 89: 5547-5551 ).
  • CMV Cytomegalovirus
  • hCMV human CMV
  • Modified promoters also may be used, including insertion and deletion mutation of native promoters and combinations or permutations thereof.
  • One example of a modified promoter is the "minimal CMV promoter" as described by Gossen and Bujard (Proc. Natl. Acad. Sci. USA, 1992, 89: 5547-5551 ).
  • any promoter can be tested readily for its effectiveness in the tetracycline- responsive expression system described herein by substitution for the minimal CMV promoter described herein.
  • the CMV minimal promoter comprises the sequence (SEQ ID NO:1):
  • the CMV promoter comprises the sequence (SEQ ID NO:2):
  • the transcriptional regulatory region present in the polynucleotide of the invention may further comprise additional sequences that help to regulate the activity of the promoter, such as enhancer sequences.
  • Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' or 3' to the transcription unit.
  • enhancers can be within an intron as well as within the coding sequence itself.
  • Enhancers usually function to increase transcription from nearby promoters. Enhancers can also contain response elements that mediate the regulation of transcription. While many enhancer sequences are known from mammalian genes (globin, elastase, albumin, fetoprotein, and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression. Preferred examples are the CMV enhancer, the SV40 enhancer, the polyoma enhancer and adenovirus enhancers. In a preferred embodiment, the polynucleotides of the invention comprise the CMV enhancer having the sequence (SEQ ID NO:3).
  • a preferred minimal promoter to be used for a transcription control sequence in accordance with the present invention has a nucleic acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO:2. It will, of course, be understood that variants of the said minimal promoter shown in SEQ ID NO: 1 having a nucleic acid sequence which is at least 70 percent, at least 80 percent, at least 90 percent, at least 95 percent, at least 97, at least 98 percent or at least 99 percent identical to the sequence as shown in SEQ ID NO: 1 or 2 or variants which hybridize thereto, preferably, under stringent hybridization conditions, are also contemplated by the present invention provided that the variants retain the properties of a minimal promoter as set forth above.
  • binding site for a transcriptional repressor refers to a sequence which is capable of specifically binding to a transcriptional repressor.
  • the binding site for a transcriptional repressor is a tet operator sequence motif.
  • tet operator sequence motif, "tet operator”, or “tetO” as used herein is intended to encompass all classes of tet operator sequences. Preferably, it relates to tetO(A), tetO (B), tetO (C), tetO (D), tetO (E), tetO (G), tetO (H), tetO(J) and tetO (Z).
  • Tet operator sequences are also disclosed in US 5,464,758 .
  • the transcriptional regulatory sequence for use in the vector of the invention contains sufficient tet operator sequences to bind to the tetR sequences described below.
  • the tetO sequences include at least one copy of the 0-1 and O-2 sequences of the tetO.
  • the tet operator sequence comprises at least one copy of the 19 bp inverted repeat sequence of operator O2 (upper strand: 5'-CCCTATCAGTGATAGAG-3') (SEQ ID NO:4).
  • the vector contains multiple copies of these sequences in tandem arrangement, e.g., one copy of the 0-1 or O-2 sequence, followed by another copy of the 0-1 or O-2 sequence.
  • the tet operator sequence comprises at least two copies of the 19 bp inverted repeat sequence of operator O2 (upper strand: 5'-CCCTATCAGTGATAGA GATCTCCCTATC AGTGATAGAG -3') (SEQ ID NO:5).
  • the vector contains at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10 or more tandem copies of the 0-1 and/or O-2 sequences in tandem.
  • one of skill in the art can readily generate a vector containing more than three copies of these tetO sequences.
  • the tet operator sequences see, e.g., I. Kaffenberger, J Biol.
  • the first promoter and the binding site for a transcriptional repressor are arranged so that the binding of the transcriptional repressor to said binding site inhibits the transcriptional activity of the promoter.
  • this can achieved by positioning the binding site for a transcriptional repressor at a suitable distance from the TATA box in the promoter so that the repressor binds to the same side of the DNA helix as the TATA-binding protein.
  • This is typically achieved when the binding site for the transcriptional repressor begins at a position between 6 and 100 nucleotides (and preferably between 6 and 24 nucleotides) downstream from the TATA element in the promoter region.
  • the binding site for a transcriptional repressor is located downstream of the first promoter.
  • the relative orientation between the promoter region and the binding site for a transcriptional repressor as well as the optimal distance between both regions in order to prevent transcription driven by the promoter when the transcriptional repressor is bound to the binding site can be determined by routine experimentation using a method as described in WO9900510 . According to these methods, a plasmid comprising a reporter gene under operative control from a promoter and the binding site for a transcriptional repressor is introduced in a host cell and the transcriptional activity of the reporter gene is determined in a cell which expresses the transcriptional repressor.
  • the expression "that the binding of the transcriptional repressor to said binding site inhibits the transcriptional activity of the promoter” is to be understood that the placement of the binding of the transcriptional repressor in the vicinity of the promoter results in at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% of inhibition in the transcription of a gene operatively linked to the promoter when compared to the transcription driven by the promoter in the absence of a neighboring binding site for a transcriptional repressor.
  • the transcriptional regulatory sequence according to the invention comprises the human cytomegalovirus (hCMV) immediate early promoter and at least one tet operator sequence located 3' with respect to the TATA box in the CMV promoter.
  • the transcriptional regulatory sequence according to the invention comprises the human cytomegalovirus (hCMV) immediate early promoter and two tandem tet operator sequences located 3' with respect to the TATA box in the CMV promoter.
  • each of the tet operator sequences has the sequence CCCTATCAGTGATAGAG (SEQ ID NO:6).
  • the transciption regulatory sequence according to the invention comprises the sequence (SEQ ID NO:7) wherein the underlined region corresponds to the CMV promoter and the double underlined regions correspond to the Tet operator sequences.
  • the second component of the all-in-one vector according to the invention is an expression cassette comprising a polynucleotide encoding a regulatable transcriptional repressor under the operative control of a second promoter wherein said regulatable transcriptional repressor is capable of specifically binding to the binding site in the transcriptional regulatory sequence in the absence but not in the presence of a ligand of said repressor, wherein the regulatable transcriptional repressor is the tetracycline repressor, and wherein the second promoter is selected from the group consisting of the Spleen Focus Forming Virus (SFFV) Long Term Repeat (LTR) promoter and the Elongation Factor 1alpha (EF1 ⁇ ) promoter.
  • SFFV Spleen Focus Forming Virus
  • LTR Long Term Repeat
  • EF1 ⁇ Elongation Factor 1alpha
  • expression cassette refers to a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements, which permit transcription of a particular nucleic acid in a target cell
  • regulatable transcriptional repressor refers to a molecule capable of inhibiting the expression of a particular gene from a promoter in a regulatable manner, i.e. that it can be turned “on” or “off” regulated by the presence or absence of biotic or abiotic factors. In effect, the molecule "represses” the expression of the gene from its promoter in the presence or absence of a given inducer molecule, which is typically a ligand of said repressor.
  • the tet repressor is a protein that represses gene transcription of the tet operon upon binding to its cognate tet operator sequences within the operon promoter in the absence of a cognate ligand (tetracycline) but not in the presence of the ligand.
  • inducible repressors include: chemically- regulated repressors, including repressors whose transcriptional activity is regulated by the presence or absence of alcohol, tetracycline, steroids, metal and other compounds; and physically-regulated repressors, including repressors whose transcriptional activity is regulated by the presence or absence of light and low or high temperatures.
  • Examples chemically inducible repressors can have hormone-responsive elements (HREs), metal-responsive elements (MREs), heat shock-responsive elements (HSREs), tetracycline operator sequence (TetO) and interferon-responsive elements (IREs).
  • HREs hormone-responsive elements
  • MREs metal-responsive elements
  • HREs heat shock-responsive elements
  • TetO tetracycline operator sequence
  • IREs interferon-responsive elements
  • the regulatable transcriptional repressor is a Tet repressor.
  • Tet repressor refers to a protein occurring in nature or modified forms thereof which combines high affinity for its cognate DNA sequence (tetO) with sensitive induction by tetracycline (tc) and especially the more potent analogs doxycycline (dox) and anhydrotetracycline (ate).
  • tetO cognate DNA sequence
  • tc tetracycline
  • dox doxycycline
  • ate anhydrotetracycline
  • the tetracycline-dependent transcriptional regulator binds to the tet operator in the absence of tetracycline or analog thereof (so-called "authentic tetracycline-dependent transcriptional activators" or "tTA”) while in the presence of tetracycline the repressor does not longer bind to the cognate operator sequences.
  • Preferred tetracycline-dependent transcriptional regulators having said properties are disclosed in US5,464,758 , US6,914,124 , US5,789,156 , US6,271,348 , WO96/01313 , or WO00/75347 .
  • "repression" of transcription is intended to mean a diminution in the level or amount of transcription of a target nucleic acid sequence compared to the level or amount of transcription prior to regulation by the transcriptional silencer protein. Transcriptional inhibition may be partial or complete.
  • Tet repressor includes wild-type repressor and mutated Tet repressors.
  • wild-type Tet repressor is intended to describe a protein occurring in nature which represses transcription from Tet operator sequences in prokaryotic cells in the absence of tetracycline.
  • the term is intended to include repressors of different class types, such as but not limited to, TetR(A), TetR(B), TetR(C), TetR(D), TetR(E), TetR(G), TetR(H), TetR(J), and TetR(Z).
  • TetR(A), TetR(B), TetR(C), TetR(D), TetR(E), TetR(G), TetR(H), TetR(J), and TetR(Z) In light of the high degree of sequence conservation (at least 80 percent) among members of each class of Tet repressor, a single member of each class of Tet repressor is used herein as representative of the entire class. Accordingly, the teaching of the present invention with respect to a specific
  • TetR(A) class is represented by the Tet repressor carried on the Tnl721 transposon ( Allmeir et al. (1992) Gene 111: 11-20 ; NCBI (National Library of Medicine, National Center for Biotechnology Information) accession number X61367 and database cross reference number (Gl:) for encoded protein sequence GL48198).
  • the TetR(B) class is represented by a Tet repressor encoded by a TnlO tetracycline resistance determinant ( Postle et al. (1984) Nucleic Acids Research 12(12): 4849-63 , Accession No. X00694, G 43052).
  • TetR(C) class is represented by the tetracycline repressor of the plasmid pSCIOl ( Brow et al. (1985) Mol. Biol. Evol 2(1): 1-12 , Accession No. M36272, GL150496).
  • TetR(D) class is represented by the Tet repressor identified in Salmonella ordonez ( Allard et al. (1993) Mol. Gen. Genet. 237: 301-5 , Accession No. X65876, GL49075).
  • TetR(E) class is represented by a Tet repressor isolated from a member of Enterobacteriaceae ( Tovar et al. (1988) Mol Gen. Genet. 215(1): 76-80 , Accession No. M34933, GI: 155020).
  • TetR(G) class is represented by a Tet repressor identified in Nibrio anguillarum ( Zhao et al. (1992) Microbiol Immunol 36: 1051-60 , Accession No. S52438, GT.262929).
  • TetR(H) class is represented by a Tet repressor encoded by plasmid pMNl 11 isolated from Pasteurella multocida ( Hansen et al. (1993) Antimicrob. Agents. Chemother. 37(12): 2699-705 , Accession No. U00792, G 392872).
  • the TetR(J) class is represented by a Tet repressor cloned from Proteus mirabilis ( Magalhaes et al. (1998) Biochim. Biophys. Acta. 1443(1-2): 262-66 , Accession No. AF038993, GL4104706).
  • the TetR(Z) class is represented by a Tet repressor encoded by the pAGl plasmid isolated from the gram-positive organism Corynebacterium glutamicum ( Tauch et al. (2000) Plasmid 44(3): 285-91 , Accession No. AAD25064, G 4583400).
  • mutated Tet repressor is intended to include polypeptides having an amino acid sequence which is similar to a wild-type Tet repressor but which derives from the wild-type repressor by substitution of one or more amino acids, deletion of one or more amino acids or addition of one or more amino acids and which substantially preserve their ability to interact with the Tet operator sequences in the absence of the tetracycline analog.
  • the ability of a mutated Tet repressor to bind to the Tet operator sequences can be determined by the skilled person by routine experimentation by providing a cell comprising a nucleic acid molecule comprising a Tet operator sequence operatively linked to a reporter gene (e.g.
  • the Lac repressor which controls the expression of a gene encoding an selectable marker (e.g., drug resistance). Binding of the mutated or variant Tet repressor to tet operator sequences in the host cell will inhibit expression of the Lac repressor in the absence of tetracycline, thereby inducing expression of the selectable marker gene. Cells expressing the marker gene are selected based upon the selectable phenotype (e.g., drug resistance).
  • an selectable marker e.g., drug resistance
  • mutated Tet repressor includes repressors that confers the ability of the inducer specific TetR to preferentially bind to a certain tetracycline analog or type of tetracycline analog.
  • An inducer specific modified TetR has inducer affinity distinction between tetracycline analogs, wherein the modified TetR binds certain tetracycline analogs but not others. For instance, the mutated Tet repressor tetracycline analogs lacking the 4-dma grouping and does not bind tc or tc analogs with a 4-dma grouping
  • additional suitable mutated Tet repressors can be created by mutagenesis of a wild type Tet repressor and selection as described in US 5,789,156 (Example 1).
  • the nucleotide and amino acid sequences of wild-type class B Tet repressors are disclosed in Hillen, W. and Schollmeier, K. (1983) Nucl. Acids Res. 11:525-539 and Postle, K. et al. (1984) Nucl. Acids Res. 12:4849-4863 .
  • a mutated Tet repressor can be created and selected, for example as follows: a nucleic acid (e.g., DNA) encoding a wild-type Tet repressor is subjected to random mutagenesis and the resultant mutated nucleic acids are incorporated into an expression vector and introduced into a host cell for screening.
  • a screening assay e.g., which allows for selection of a Tet repressor which binds to a Tet operator sequence only in the absence of a substituted tetracycline compound can be used.
  • a library of mutated nucleic acids in an expression vector can be introduced into an E. coli strain in which Tet operator sequences control the expression of a gene encoding a Lac repressor and the Lac repressor controls the expression of a gene encoding an selectable marker (e.g., drug resistance). Binding of a Tet repressor to Tet operator sequences in the bacteria will inhibit expression of the Lac repressor, thereby inducing expression of the selectable marker gene. Cells expressing the marker gene are selected based upon the selectable phenotype (e.g., drug resistance). For wild-type Tet repressors, expression of the selectable marker gene will occur in the absence of tetracycline.
  • Tet operator sequences control the expression of a gene encoding a Lac repressor and the Lac repressor controls the expression of a gene encoding an selectable marker (e.g., drug resistance). Binding of a Tet repressor to Tet operator
  • a nucleic acid encoding a mutated Tet repressor may be selected using this system based upon the ability of the nucleic acid to induce expression of the selectable marker gene in the bacteria only in the presence of a substituted tetracycline compound.
  • chimeric tetracycline repressor or “chimeric revTetR”.
  • chimeric tetracycline repressor is intended to include polypeptides having an amino acid sequence comprising amino acid residues derived from more than one type of tetracycline repressor.
  • the term is intended to include chimeric tetracycline repressors constructed from different class types, such as but not limited to, TetR(A), TetR(B), TetR(C), TetR(D), TetR(E), TetR(G), TetR(H), TetR(J), and TetR(Z).
  • the chimeric tetracycline repressors comprise an amino-terminal DNA-binding domain and a carboxy-terminal tetracycline binding domain, including but not limited to the corresponding domains of the TetR(A), TetR(B), TetR(C), TetR(D), TetR(E), TetR(G), TetR(H), TetR(J), and TetR(Z).
  • Such chimeric tetracycline repressors further comprise at least one amino acid substitution that confers the reverse phenotype.
  • a chimeric revTetR retains the DNA binding specificity of the DNA binding domain of a wild-type Tet repressor.
  • this reverse phenotype of the chimeric revTetR is displayed a eukaryote.
  • the transcriptional repressor used in the present invention may further comprise one or more copies of a nuclear localization signal.
  • a nuclear localization signal means an amino acid sequence known to, in vivo, direct a protein disposed in the cytoplasm of a cell across the nuclear membrane and into the nucleus of the cell. This is particularly useful in the case of transcriptional repressors of bacterial origin when they are used in eukaryotic cells since they are devoid of naturally occurring NLSs.
  • a variety of nuclear localization signals are known and selection of an appropriate sequence can be made based on the known properties of these various sequences.
  • Representative NLSs include monopartite sequences such as that from SV40 large T antigen and the c-myc proto-oncogene.
  • Bipartite signals are characterized as a small cluster of basic residues positioned 10-12 residues N-terminal to a monopartite-like sequence.
  • An example of a bipartite nuclear localization signal is that from nucleoplasmin.
  • a NLS selected from the following list may be conjugated to the oligonucleotide: SV40 large T Antigen: PKKKRKV (SEQ ID NO: 8); Nucleoplasmin: KRPAAIKKAGQ AKKKK (SEQ ID NO: 9); CBP80: RRRHSDENDGGQPHKRRK (SEQ ID NO: 10); HIV-I Rev: RQARRNRRRWE (SEQ ID NO: 11); HTLV-I Rex: MPKTRRRPRRSQRKRPPT (SEQ ID NO: 12); hnRNP A: NQSSNFGPMKGGNFGGRSSGP YGGGGQ YFAKPRNQGGY (SEQ ID NO: 13); c-myc PAAKRVKLD (SEQ ID NO: 14) and rpL23a: VHSHKKKKIRTSPTFTTPKTLRLRRQPKYPRKSAPRRNKLDHY (SEQ ID NO: 15).
  • the nuclear localization signal comprises the motif K (K/R) X (K/R) (SEQ ID NO: 16).
  • the nuclear localization signal is KRXR (SEQ ID NO: 17), wherein X is any amino acid.
  • the NLS may be present at any position in the transcriptional repressor, although it is preferably present at the C-terminus.
  • the regulatable transcriptional repressor is under the operative control of a second promoter.
  • the terms "under the operative control” and “operatively linked” are used herein interchangeably to refer to two nucleic acids are either physically linked or are functionally linked so that at least one of the nucleic acids can act on the other nucleic acid.
  • the transcription control sequence of the present invention and a nucleic acid sequence to be expressed are operatively linked if the expression of the nucleic acid sequence can be governed by the said transcription control sequence. Accordingly, the transcription control sequence and the nucleic acid sequence to be expressed may be physically linked to each other, e.g., by inserting the transcription control sequence at the 5 'end of the nucleic acid sequence to be expressed.
  • the transcription control sequence and the nucleic acid to be expressed may be merely in physical proximity so that the transcription control sequence is functionally linked to the nucleic acid sequence to be expressed.
  • the transcription control sequence and the nucleic acid to be expressed are, preferably, separated by not more than 1,500 bp, 500 bp, 300 bp, 100 bp, 80 bp, 60 bp, 40 bp, 20 bp, 10 bp or 5 bp.
  • the term "promoter” has been defined in detail in respect of the transcriptional regulatory sequence of the vector of the invention and is usually with the same meaning in the context of the expression cassette.
  • the second promoter is a promoter functional in mammalian cells.
  • the second promoter is the Spleen Focus Forming Virus (SFFV) Long Term Repeat (SFFV LTR) promoter (hereinafter SFFV promoter) as described by Joyner et al. (Proc. Natl. Acad. Sci. USA, 1982, 79: 1573-7 ).
  • the second promoter is the EF1 ⁇ promoter.
  • polynucleotides comprised in the lentiviral vectors according to the present invention may further comprise regions adequate for inserting a polynucleotide of interest so that said polynucleotide is under operative control of the transcriptional regulatory region.
  • the polynucleotide comprised in the lentiviral vector of the invention comprises a polylinker downstream of the transcriptional regulatory region.
  • polylinker and “multiple cloning site” are used herein interchangeably to refer to refer to a region of DNA that contains one or more commonly used restriction sites allowing the insertion of a DNA fragment (e.g., gene of interest) into the expression construct.
  • the polynucleotide comprised in the lentiviral vector according to the present invention may further comprise a polynucleotide of interest under operative control of the transcriptional regulatory region.
  • a polynucleotide of interest under operative control of the transcriptional regulatory region.
  • Particularly preferred polynucleotides include reporter genes, when the polynucleotides are used as research tools or for imaging purposes, polynuclotides encoding polypeptides when the polynucleotides are used for gene therapy in diseases characterised by a lack of function of said polypeptide and polynucleotides which are capable of silencing the expression of target genes, adequate in those cases wherein the lentiviral vectors according to the invention are used for the treatment of diseases associated with an excessive expression of a given gene, either endogenous to the organism being treated or heterologous.
  • Examples of polynucleotides of interest that can be inserted downstream of the transcriptional regulatory region are provided below in the context of the therapeutic and non-therapeutic uses of the lentiviral vectors of the invention.
  • vector is intended to include a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • the term also relates to targeting constructs which allow for random or site-directed integration of the targeting construct into genomic DNA.
  • targeting constructs preferably, comprise DNA of sufficient length for either homologous recombination or heterologous integration as described in detail below.
  • the lentivral vector encompassing the transcription control sequence of the present invention preferably, further comprises selectable markers for propagation and/or selection in a host.
  • a vector may be characterized by one or a small number of restriction endonuclease sites at which such DNA sequences may be cut in a determinable fashion without the loss of an essential biological function of the vector, and into which a DNA fragment may be spliced in order to bring about its replication and cloning.
  • a vector may further contain a marker suitable for use in the identification of cells transformed with the vector.
  • plasmid which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome.
  • vectors having a bacterial origin of replication and episomal mammalian vectors.
  • Other vectors e. g., non-episomal mammalian vectors
  • Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors".
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector can be used interchangeably as the plasmid is the most commonly used form of vector.
  • other forms of expression vectors such as viral vectors (e. g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions, are also disclosed.
  • the lentiviral vector of the present invention is an expression vector. More preferably, in the lentiviral vector of the invention, the transcription control sequence is operatively linked to a nucleic acid sequence to be expressed. Such operative linkage, preferably, allows expression of the said nucleic acid sequence in eukaryotic cells or isolated fractions thereof.
  • regulatory elements ensuring expression in eukaryotic cells are well known in the art. They, preferably, comprise regulatory sequences ensuring initiation of transcription as comprised by the transcription control sequence as well as poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may be included into the vector such as transcriptional as well as translational enhancers.
  • Lentiviral vectors are one of the most promising vectors for gene transfer in primary human cells, they are highly efficient and do not express any viral gene that could alter normal cellular physiology.
  • lentivirus refers to a group (or scientific genus) of retroviruses that in nature give rise to slowly developing disease due to their ability to incorporate into a host genome. Modified lentiviral genomes are useful as viral vectors for the delivery of a nucleic acid sequence to a cell. An advantage of lentiviruses for infection of cells is the ability for sustained transgene expression.
  • viruses include in particular Human Immunodeficiency Virus type 1 (HIV-1), Human Immunodeficiency Virus type 2 (HIV-2), Simian Immunodeficiency Virus (SIV), Feline Immunodeficiency Virus (FIV), Equine Infectious Anaemia Virus (EIAV), Bovine Immunodeficiency Virus (BIV), Visna Virus of sheep (VISNA) and Caprine Arthritis-Encephalitis Virus (CAEV).
  • HV-1 Human Immunodeficiency Virus type 1
  • HV-2 Human Immunodeficiency Virus type 2
  • SIV Simian Immunodeficiency Virus
  • FV Feline Immunodeficiency Virus
  • EIAV Equine Infectious Anaemia Virus
  • BIV Bovine Immunodeficiency Virus
  • VISNA Visna Virus of sheep
  • CAEV Caprine Arthritis-Encephalitis Virus
  • Lentiviral vectors are well known in the art (see, for example, Naldini et al., Science, 272(5259):263- 267, 1996 ; Zufferey et al., Nat Biotechnol, 15(9):871-875, 1997 ; Blomer et al., J Virol, 71(9):6641-6649, 1997 ; U.S. Pat. Nos. 6,013,516 and 5,994,136 ).
  • Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both in vivo and ex vivo gene transfer and expression of nucleic acid sequences.
  • recombinant lentivirus capable of infecting a non-dividing cell wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely gag, pol and env, as well as rev and tat is described in U.S. Pat. No. 5,994,136 .
  • One may target the recombinant virus by linkage of the envelope protein with an antibody or a particular ligand for targeting to a receptor of a particular cell-type.
  • a sequence (including a regulatory region) of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target-specific.
  • the recombinant lentiviruses according to the invention may be genetically modified in such a way that certain genes constituting the native infectious virus are eliminated and replaced with a nucleic acid sequence of interest to be introduced into the target cells.
  • the lentiviral vector can integrate into the genome of the host cell.
  • the genetic material thus transferred is then transcribed and possibly translated into proteins inside the host cell.
  • the lentiviral vector is a non integrative lentiviral vector, the vector is present in episomal forms.
  • the lentiviral vector according to the present invention in addition to the transcriptional regulatory sequence and the expression cassette as described above, may further comprise additional elements which help to improve expression of the genes encoded within the vector.
  • the lentiviral vector is another form of self-inactivating (SIN) vector as a result of a deletion in the 3' long terminal repeat region (LTR).
  • the vector contains a deletion within the viral promoter.
  • the LTR of lentiviruses such as the HIV LTR contains a viral promoter.
  • this promoter is relatively inefficient, when transactivated by e.g. tat, the promoter is efficient because tat-mediated transactivation increases the rate of transcription about 100 fold.
  • the presence of the viral promoter can interfere with heterologous promoters operably linked to a transgene. To minimize such interference and better regulate the expression of transgenes, the lentiviral promoter may be deleted.
  • the lentiviral vector comprises, in the 5' to 3' orientation:
  • the invention in another embodiment, relates to a host cell which comprises a lentiviral vector according to the present invention.
  • a "host cell” includes any cultivatable cell that can be modified by the introduction of heterologous DNA.
  • a host cell is one in which the transcriptional repressor encoded by the polynucleotide of the invention protein can be stably expressed, post-translationally modified, localized to the appropriate subcellular compartment, and made to engage the appropriate transcription machinery.
  • the choice of an appropriate host cell will also be influenced by the choice of detection signal.
  • reporter constructs can provide a selectable or screenable trait upon activation or inhibition of gene transcription in response to a transcriptional regulatory protein; in order to achieve optimal selection or screening, the host cell phenotype will be considered.
  • a host cell of the present invention includes prokaryotic cells and eukaryotic cells.
  • Prokaryotes include gram negative or gram positive organisms, for example, E. coli or Bacilli. It is to be understood that prokaryotic cells will be used, preferably, for the propagation of the transcription control sequence comprising polynucleotides or the vector of the present invention.
  • Suitable prokaryotic host cells for transformation include, for example, E.
  • Eukaryotic cells include, but are not limited to, yeast cells, plant cells, fungal cells, insect cells (e.g., baculovirus), mammalian cells, and the cells of parasitic organisms, e.g., trypanosomes.
  • yeast includes not only yeast in a strict taxonomic sense, i.e., unicellular organisms, but also yeast-like multicellular fungi of filamentous fungi.
  • Exemplary species include Kluyverei lactis, Schizosaccharomyces pombe, and Ustilaqo maydis, with Saccharomyces cerevisiae being preferred.
  • Other yeasts which can be used in practicing the present invention are Neurospora crassa, Aspergillus niger, Aspergillus nidulans, Pichia pastoris, Candida tropicalis, and Hansenula polymorpha.
  • Mammalian host cell culture systems include established cell lines such as COS cells, L cells, 3T3 cells, Chinese hamster ovary (CHO) cells, embryonic stem cells, with BHK, HeK or HeLa cells being preferred.
  • Eukaryotic cells are, preferably, used to for recombinant gene expression by applying the transcription control sequence or the expression vector of the present invention.
  • the host cell of the invention may be obtained by contacting a cell with a vector of the invention under conditions adequate for the incorporation of the vector into a host cell.
  • the vector may be incorporated into a host cell by various techniques well known in the art. Suitable methods for nucleic acid delivery for transformation of a cell, a tissue or an organism for use with the current invention are believed to include virtually any method by which a nucleic acid (e.g., DNA) can be introduced into a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art.
  • a nucleic acid e.g., DNA
  • Such methods include, but are not limited to, direct delivery of DNA such as by ex vivo transfection ( Wilson et al., Science, 244:1344-1346, 1989 , Nabel and Baltimore, Nature 326:711-713, 1987 ), optionally with Fugen (Roche) or Lipofectamine (Invitrogen), by injection ( U.S. Pat. Nos. 5,994,624 , 5,981,274 , 5,945,100 , 5,780,448 , 5,736,524 , 5,702,932 , 5,656,610 , 5,589,466 and 5,580,859 , including microinjection ( Harland and Weintraub, J. Cell Biol, 101: 1094-1099, 1985 ; U.S. Pat.
  • the host cell is capable of integrating one or more copies of said vector in the genome.
  • the expression level of the transcriptional repressor will depend on the strength of the promoter to which it is operatively linked and on the number of copies of the vector in the host cell.
  • the cells preferably contain at least 2 copies of the vector integrated.
  • maximal responsiveness can be reached when the cells have an average of 4 vectors copies of the vector.
  • the host cell according to the invention contains at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 and at least 10 copies of the polynucleotide of the invention integrated in the genome. In a still more preferred embodiment, the host cell according to the invention contains between 2 and 4 copies of the vector of the invention integrated in the genome.
  • the vector contains, preferably, the SFFV promoter as second promoter.
  • the invention in another embodiment, relates to a lentiviral particle comprising the polynucleotide of the invention.
  • lentiviral particle refers to a recombinant lentivirus which carries at least one gene or nucleotide sequence of interest, which is generally flanked by lentiviral LTRs.
  • the lentivirus may also contain a selectable marker.
  • the recombinant lentivirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection.
  • the components of the particle may be modified with respect to the wild type lentivirus.
  • the Env proteins in the proteinaceous coat of the particle may be genetically modified in order to alter their targeting specificity or achieve some other desired function.
  • Lentiviral particles according to the invention can be obtained by contacting a suitable packaging cell with a lentiviral vector according to the invention and with one or more trans-complementing helper viruses which comprises the lentiviral genes needed for packaging of the lentiviral vector into vector capsids.
  • the lentiviral particles are obtained using two helper plasmids.
  • a first plasmid for trans-complementation provides a nucleic acid encoding the protein products of the gag and pol lentiviral genes and which is devoid of encapsidation sequence, of sequence encoding an envelope and, advantageously, is also devoid of lentiviral LTRs (the packaging plasmid).
  • gag and pol proteins are advantageously placed under control of a heterologous promoter, for example a viral, cellular, etc. promoter, which may be constitutive or regulated, weak or strong.
  • a heterologous promoter for example a viral, cellular, etc. promoter, which may be constitutive or regulated, weak or strong.
  • This plasmid allows the expression of all the proteins necessary for the formation of empty virions, except the envelope glycoproteins. It is understood that the gag and pol genes may also be carried by different plasmids.
  • a third plasmid provides a nucleic acid which allows the production of the chosen envelope (env) glycoprotein (the envelope plasmid). This vector is preferentially devoid of all lentiviral sequences.
  • the three vectors used do not contain any homologous sequence sufficient to allow a recombination.
  • the nucleic acids encoding gag, pol and env may advantageously be cDNAs prepared according to conventional techniques, from sequences of the viral genes available in the prior art and on databases.
  • the vectors described above are introduced into competent cells and the viruses produced are harvested.
  • the cells used may be any competent cell, preferably mammalian cell, for example animal or human cell, which is non pathogenic. Mention may, for example, be made of 293 cells, embryonic cells, fibroblasts, muscle cells, etc.
  • a preferred method for preparing a non replicative recombinant lentivirus comprises transfecting a population of competent cells with a combination of vectors (two vectors, three vectors or more than three vectors) as described above, and recovering the viruses thus produced.
  • the lentiviruses of the invention may also be prepared, as explained previously, from an encapsidation cell line producing one or more gag, pol and env proteins.
  • the lentiviral vector of the invention is used as an all-in-one of vector since it allows for a single step generation of the responsive primary cell lines and for gene therapy strategies
  • vector systems wherein the different elements of the all-in-one vector (the transcriptional regulatory sequence and the expression cassette) are provided in different polynucleotides are also disclosed.
  • the disclosure relates to a composition or kit-of-parts comprising
  • the kit can be used to regulate the expression of a gene of interest (i.e., a nucleotide sequence of interest to be transcribed) which can be cloned under operative control of the transcription regulatory unit.
  • a gene of interest i.e., a nucleotide sequence of interest to be transcribed
  • eukaryotic cells which have nucleic acid encoding a transactivator and/or inhibitor fusion protein stably incorporated therein, such that the transactivator and/or inhibitor fusion protein are expressed in the eukaryotic cell, may be provided in the kit.
  • kit refers to a collection of the aforementioned compounds, means or reagents of the present invention which may or may not be packaged together.
  • the components of the kit may be comprised by separate vials (i.e. as a kit of separate parts) or provided in a single vial.
  • the kit of the present invention is to be used for practising the methods referred to herein above. It is, preferably, envisaged that all components are provided in a ready-to-use manner for practising the methods referred to above.
  • the kit preferably contains instructions for carrying out the said methods.
  • the instructions can be provided by a users manual in paper- or electronic form.
  • the manual may comprise instructions for interpreting the results obtained when carrying out the aforementioned methods using the kit of the present disclosure.
  • the kit includes a carrier means having in close confinement therein at least two container means: a first container means which contains the polynucleotide comprising the regulatable transcriptional sequence and a second container means which contains the expression cassette.
  • the first polynucleotide typically comprises a cloning site for introduction of a nucleotide sequence to be transcribed (optionally including an operatively linked minimal promoter sequence) and at least one operatively linked tet operator sequence.
  • the term "cloning site" is intended to encompass at least one restriction endonuclease site. Typically, multiple different restriction endonuclease sites (e.g., a polylinker) are contained within the nucleic acid.
  • polynucleotide "transcriptional regulatory sequence”, “promoter”, “binding site for a transcriptional repressor”, “expression cassette” and “regulatable transcriptional repressor” and “operative control” have been described in detail in the context of the polynucleotide of the invention and are used with the same meaning in the context of the composition or kit-of-parts of the disclosure.
  • the first and the second promoter are different promoters.
  • the first promoter is the CMV immediate early promoter.
  • the binding site for a transcriptional repressor is a binding site for the tetracycline repressor and wherein the regulatable transcriptional repressor is the tetracycline repressor.
  • the binding site for the tetracycline repressor is a TetO operator sequence.
  • the binding site for the transcriptional repressor is downstream of the first promoter.
  • the second promoter is the SFFV promoter.
  • composition or kit-of-parts of the disclosure further comprises a polynucleotide of interest under operative control of the transcriptional regulatory sequence. Suitable polynucleotides of interest are defined below in the context of the uses of the compositions and kits-of-parts of the disclosure.
  • the first and/or the second promoter are provided forming part of a vector.
  • the vector is a lentiviral vector.
  • the lentiviral vector is an integrative lentiviral vector.
  • the terms "vector”, “lentiviral vector” and "integrative lentiviral vector” have been described in detail above in respect of the lentiviral vector of the invention.
  • the invention in another aspect, relates to a composition or kit-of-parts comprising the lentiviral vector of the invention and a ligand of the transcriptional repressor which, when bound to the repressor, results in the inactive repressor which is no longer capable of binding to its binding site in the transcriptional regulatory sequence.
  • the transcriptional repressor is a tetracycline repressor and the ligand is tetracycline or a tetracycline analog.
  • tetracycline analog is intended to include compounds which are structurally related to tetracycline and which bind to the Tet repressor referred to herein below with a IQ of at least about 10 -6 M.
  • the tetracycline analog binds with an affinity of about 10 -9 M or greater.
  • Preferred tetracycline analogs are anhydrotetracycline (ate), doxycycline (dox), chlorotetracycline, oxytetracycline, or deoxytetracycline. Further analogs are disclosed by Hlavka and Boothe, "The Tetracyclines," in Handbook of Experimental Pharmacology 78, R. K. Blackwood et al. (eds.), Springer- Verlag, Berlin, N.Y., 1985 ; Mitscher, "The Chemistry of the Tetracycline Antibiotics", Medicinal Research 9, Dekker, N.
  • tetracycline analogs encompass those which are disclosed in WO2007/133797 and WO2007/133798 .
  • polynucleotides which form the compositions or kits-of-parts according to the invention are provided as lentiviral expression vectors.
  • the polynucleotides may further comprise one or more elements selected from the group consisting of:
  • a polynucleotide sequence operatively linked to the transcriptional regulatory sequence and an expression cassette comprising a polynucleotide encoding a regulatable transcriptional repressor under the operative control of a second promoter allows high level transcription of the nucleotide sequence operatively linked to the transcriptional regulatory sequence in the presence of a ligand of the regulatable transcriptional repressor, whereas transcription does not occur in the absence of the ligand of the regulatable transcriptional repressor.
  • the level of basal transcription of the nucleotide sequence may vary depending upon the host cell and site of integration of the sequence, but is generally quite low or even undetectable in the absence of a ligand of the transcriptional repressor.
  • the host cell is contacted with a ligand for the transcriptional repressor wherein said regulatable transcriptional repressor is capable of specifically binding to the binding site in the transcriptional regulatory sequence in the absence but not in the presence of a ligand thereof.
  • the invention relates to an in vitro method for regulating the expression of a nucleic acid sequence of interest comprising the steps of
  • the polynucleotides, compositions and kits-of-parts according to the invention are modified so as to incorporate said polynucleotide of interest under operative control of the transcriptional regulatory sequence.
  • the binding site for a transcriptional repressor is a binding site for the tetracycline repressor, wherein the regulatable transcriptional repressor is the tetracycline repressor and wherein the ligand is tetracycline or an analog thereof.
  • tetracycline analog has been defined in detail above.
  • the cell is contacted with the tetracycline or an analog thereof by culturing the cell in a medium containing the ligand.
  • a preferred concentration range for the inducing agent is between about 10 and about 1000 ng/ml.
  • the tetracycline or analog thereof compound can be directly added to media in which cells are already being cultured, or more preferably for high levels of gene induction, cells are harvested from substituted tetracycline compound-free media and cultured in fresh media containing the desired substituted tetracycline compound.
  • mammalian, yeast or fungal cells can be modified to contain these nucleic acid molecules components as described herein.
  • the modified mammalian, yeast or fungal cells can then be cultured by standard fermentation techniques in the presence of Tc or an analogue thereof to induce expression of the gene and produce the protein of interest.
  • the disclosure provides a production process for isolating a protein of interest when the protein is toxic for the cells.
  • a host cell e.g., a yeast or fungus
  • a lentiviral vector according to the invention is grown at production scale in a culture medium in the absence of tetracycline.
  • the addition of tetracycline or a tetracycline analogue stimulates transcription of the nucleotides sequence encoding the protein of interest (i.e., the nucleotide sequence operatively linked to the tet operator sequence(s)) and the protein of interest is isolated from harvested host cells or from the culture medium. Standard protein purification techniques can be used to isolate the protein of interest from the medium or from the harvested cells.
  • cells within in a subject are contacted with the tetracycline or analog thereof by administering the compound to the subject.
  • the disclosure also provides for large scale production of a protein of interest in animals, such as in transgenic farm animals. Advances in transgenic technology have made it possible to produce transgenic livestock, such as cattle, goats, pigs and sheep (reviewed in Wall, R.J. et al. (1992) J. Cell. Biochem. 49:113-120 ; and Clark, A.J. et al. (1987) Trends in Biotechnology 5:20-24 ).
  • transgenic livestock carrying in their genome the components of the inducible regulatory system of the invention can be constructed, wherein a gene encoding a protein of interest is operatively linked to at least one tet operator sequence.
  • Gene expression, and thus protein production is induced by administering certain Tc (or analogue thereof) to the transgenic animal.
  • Protein production can be targeted to a particular tissue by incorporating into the transcriptional regulatory sequence in the lentiviral vector of the invention an appropriate tissue-specific regulatory elements which limits expression of the gene of interest to certain cells.
  • a mammary gland- specific regulatory element such as the milk whey promoter ( U.S. Patent No. 4,873,316 and European Application Publication No.
  • the protein of interest will be produced in the mammary tissue of the transgenic animal.
  • the protein can be designed to be secreted into the milk of the transgenic animal, and if desired, the protein can then be isolated from the milk.
  • the dosage is adjusted to preferably achieve a serum concentration between about 0.0005 and 1.0 ⁇ g/ml.
  • the tetracycline or analogue thereof can be administered to a subject by any means effective for achieving an in vivo concentration sufficient for gene induction.
  • suitable modes of administration include oral administration (e.g., dissolving the inducing agent in the drinking water), slow release pellets and implantation of a diffusion pump.
  • oral administration e.g., dissolving the inducing agent in the drinking water
  • slow release pellets e.g., slow release pellets
  • implantation of a diffusion pump e.g., implantation of a diffusion pump.
  • the inducing agent can be dissolved in water administered to the plant.
  • the expression of a polynucleotide of interest can be carried out in any cell wherein the first and second promoters are functional.
  • the cell is a mesenchymal stem cell.
  • mesenchymal stem cell also referred to herein as “MSC” shall be taken to mean a cell which is capable of giving rise to multiple different types of cell, originally derived from the mesenchyme.
  • the mesenchymal stem cell is a human mesenchymal stem cell.
  • modulating the concentration of a tetracycline or analog thereof means “altering the concentration of the tetracycline or analog thereof".
  • the expression of the nucleic acid to be expressed can be achieved by adding de novo an amount of tetracycline or by increasing the amount of tetracycline present in the host cell, plant or non-human transgenic animal.
  • Tetracycline or an analog thereof may be delivered to the host cell, preferably, via the culture medium which comprises the host cells.
  • tetracycline or an analog thereof may be delivered to the individual cells of the plant or non-human transgenic animal by water or nutrient supply or via infusions.
  • the regulatable gene expression system of the invention has numerous advantages properties that make it particularly suitable for application to gene therapy.
  • the system provides an "on"/"off" switch for gene expression that allows for regulated dosing of a gene product in a subject.
  • a gene of interest can be switched "on" at fixed intervals (e.g., daily, alternate days, weekly, etc.) to provide the most effective level of a gene product of interest at the most effective time.
  • the level of gene product produced in a subject can be monitored by standard methods (e.g., direct monitoring using an immunological assay such as ELISA or RIA or indirectly by monitoring of a laboratory parameter dependent upon the function of the gene product of interest, e.g., blood glucose levels and the like).
  • This ability to turn "on" expression of a gene at discrete time intervals in a subject while also allowing for the gene to be kept “off at other times avoids the need for continued administration of a gene product of interest at intermittent intervals.
  • This approach avoids the need for repeated injections of a gene product, which may be painful and/or cause side effects and would likely require continuous visits to a physician.
  • the system of the invention avoids these drawbacks.
  • the ability to turn “on” expression of a gene at discrete time intervals in a subject allows for focused treatment of diseases which involve “flare ups” of activity (e.g., many autoimmune diseases) only at times when treatment is necessary during the acute phase when pain and symptoms are evident. At times when such diseases are in remission, the expression system can be kept in the "off state.
  • the invention relates to a lentiviral vector according to the invention or a lentiviral particle according to the invention for use in medicine.
  • the lentiviral vector of the invention may be used in gene therapy approaches, in treatments for either genetic or acquired diseases.
  • the general approach of gene therapy involves the introduction of nucleic acid into cells such that one or more gene products encoded by the introduced genetic material are produced in the cells to restore or enhance a functional activity.
  • genes for reviews on gene therapy approaches see Anderson, W. F. (1992) Science 256:808-813 ; Miller, A. D. (1992) Nature 357:455-460 ; Friedmann, T. (1989) Science 244:1275-1281 ; and Cournoyer, D., et al. (1990) Curr. Opin. Biotech. 1:196-208 ).
  • Genes of particular interest to be expressed in cells of a subject for treatment of genetic or acquired diseases include those encoding adenosine deaminase, Factor VIII, Factor X, dystrophin, beta-globin, LDL receptor, CFTR, insulin, erythropoietin, anti-angiogenesis factors, growth hormone, glucocerebrosidase, beta-glucouronidase, ⁇ 1-antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, ornithine transcarbamylase, arginosuccinate synthetase, UDP-glucuronysyl transferase, apoAl, TNF, soluble TNF receptor, interleukins (e.g., IL-2), interferons (e.g., ⁇ - or ⁇ -IFN) and other cytokines and growth factors.
  • adenosine deaminase Factor VIII, Factor X
  • Cells types which can be modified for gene therapy purposes include hematopoietic stem cells, myoblasts, hepatocytes, lymphocytes, skin epithelium and airway epithelium.
  • genes and methods for gene therapy see e.g., Wilson, J.M et al. (1988) Proc. Natl Acad. Sci. USA 85:3014-3018 ; Armentano, D. et al. (1990) Proc. Natl Acad. Sci. USA 87:6141-6145 ; Wolff, J.A. et al. (1990) Science 247:1465-1468 ; Chowdhury, J.R. et al.
  • Gene therapy applications of particular interest in cancer treatment include overexpression of a cytokine gene (e.g., TNF- ⁇ ) in tumor infiltrating lymphocytes or ectopic expression of cytokines in tumor cells to induce an anti-tumor immune response at the tumor site, expression of an enzyme in tumor cells which can convert a non-toxic agent into a toxic agent, expression of tumor specific antigens to induce an anti-tumor immune response, expression of tumor suppressor genes (e.g., p53 or Rb) in tumor cells, expression of a multidrug resistance gene (e.g., MDR1 and/or MRP) in bone marrow cells to protect them from the toxicity of chemotherapy.
  • a cytokine gene e.g., TNF- ⁇
  • an enzyme in tumor cells which can convert a non-toxic agent into a toxic agent
  • tumor specific antigens to induce an anti-tumor immune response
  • tumor suppressor genes e.g., p53 or Rb
  • Gene therapy applications that may particularly benefit from this ability to modulate gene expression during discrete time intervals include the following nonlimiting examples:
  • the disclosed regulatory proteins are used to express angiogenesis inhibitors) from within a tumor via a transgene regulated by the system of the invention.
  • Expression of angiogenesis inhibitors in this manner may be more efficient than systemic administration of the inhibitor and would avoid any deleterious side effects that might accompany systemic administration.
  • restricting angiogenesis inhibitor expression to within tumors could be particularly useful in treating cancer in children still undergoing angiogenesis associated with normal cell growth.
  • high level regulated expression of cytokines may represent a method for focusing a patient's own immume response on tumor cells.
  • Tumor cells can be transduced to express chemoattractant and growth promoting cytokines important in increasing an individual's natural immune response. Because the highest concentrations of cytokines will be in the proximity of the tumor, the likelihood of eliciting an immunological response to tumor antigens is increased.
  • a potential problem with this type of therapy is that those tumor cells producing the cytokines will also be targets of the immune response and therefore the source of the cytokines will be eliminated before eradication of all tumor cells can be certain.
  • E1 9 protein from adenovirus (see e.g., Cox, Science 247:715). This protein prevents transport of class I HLA antigens to the surface of the cell and hence prevents recognition and lysis of the cell by the host's cytotoxic T cells. Accordingly, regulated expression of E1 9 in tumor cells could shield cytokine producer cells from cytotoxic T cells during the onset of an immune response provoked by cytokine expression. After a sufficient period of time has elapsed to eradicate all tumor cells but those expressing E1 9, E1 9 expression can be turned off, causing these cells then to fall victim to the provoked anti-tumor immune response.
  • a suicide gene e.g., an apoptosis gene, TK gene, etc
  • expression of a suicide gene can be triggered to eliminate cells carrying the gene therapy vector, such as cells in a bioinert implant, cells that have disseminated beyond the intended original location, etc.
  • the cells can be rapidly eliminated by induction of the suicide gene.
  • a subject's own cells are generally used, when possible, to express the therapeutic gene product, either by in vivo modification of the subject's cells or by obtaining cells from the subject, modifying them ex vivo and returning them to the subject.
  • the regulatory system of the invention in addition to regulating a therapeutic gene, can also be used to regulate one or more genes involved in the immune recognition of the cells to inhibit an immune reaction against the foreign cells.
  • cell-surface molecules involved in recognition of a foreign cell by T lymphocytes can be downmodulated on the surface of a foreign cell used for delivery of a therapeutic gene product, such as by regulated expression in the foreign cell of a ribozyme which cleaves the mRNA encoding the cell-surface molecule.
  • Particularly preferred cell surface molecules which can be down-modulated in this manner to inhibit an unwanted immune response include class I and/or class II major histocompatibility complex (MHC) molecules, costimulatory molecules (e.g., B7-1 and/or B7-2), CD40, and various "adhesion" molecules, such as ICAM-1 or ICAM-2.
  • MHC major histocompatibility complex
  • costimulatory molecules e.g., B7-1 and/or B7-2
  • CD40 e.g., CD40
  • various "adhesion" molecules such as ICAM-1 or ICAM-2.
  • the down-regulation of expression of a cell-surface molecule(s) in a host cell can be coordinated with the up-regulation of expression of a therapeutic gene. Accordingly, after therapy is completed and expression of the therapeutic gene is halted, expression of the endogenous cell surface molecule(s) can be restored to normal.
  • the invention in another embodiment, relates to lentiviral vectors for inducible and/or tissue specific expression of nucleic acid molecules, e.g., double-stranded RNA molecules, that interfere with the expression of a target gene using methods known in the art.
  • a coding region encoding a target- gene-specific antisense RNA is operatively associated with the transcriptional regulatory region so that the binding of the tetracycline or analog thereof to the operator sequence results in the expression of the antisense RNA.
  • the level of expression of an antisense RNA molecule, and translation of a target gene mRNA inhibited by the antisense RNA molecule may be modulated by the concentration of tetracyline or its analog, the level of expression of the inducer specific TetR protein, and/or the temperature.
  • the target gene corresponds to one copy of a duplicated gene in a prokaryotic organism, thereby allowing the construction of a host cell that can be functionally haploid for that gene product. Such organisms are particularly useful for the detection of anti-microbial agents active against the encoded target gene product.
  • RNA interference refers to selective intracellular degradation of RNA used to silence expression of a selected target gene.
  • RNAi is a process of sequence-specific, post-transcriptional gene silencing in organisms initiated by double- stranded RNA (dsRNA) that is homologous in sequence to the gene to be silenced.
  • dsRNA double- stranded RNA
  • the RNAi technique involves small interfering RNAs (siRNAs) that are complementary to target RNAs (encoding a gene of interest) and specifically destroy the known mRNA, thereby diminishing or abolishing gene expression.
  • RNAi is mediated by small interfering RNAs (siRNAs).
  • small interfering RNA refers to a nucleic acid molecule which is a double stranded RNA agent that is complementary to i.e., able to base-pair with, a portion of a target RNA (generally mRNA).
  • siRNA acts to specifically guide enzymes in the host cell to cleave the target RNA.
  • siRNA is able to cause cleavage of the target RNA strand, thereby inactivating the target RNA molecule.
  • the complementary regions of the siRNA allow sufficient hybridization of the siRNA to the target RNA and thus mediate RNAi.
  • siRNAs are approximately 21-25 nucleotides in length.
  • the siRNA sequence needs to be of sufficient length to bring the siRNA and target RNA together through complementary base-pairing interactions.
  • the siRNA used with the Tet expression system of the invention may be of varying lengths.
  • the length of the siRNA is preferably greater than or equal to ten nucleotides and of sufficient length to stably interact with the target RNA; specifically 15-30 nucleotides; more specifically any integer between 15 and 30 nucleotides, such as 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30.
  • sufficient length is meant an oligonucleotide of greater than or equal to 15 nucleotides that is of a length great enough to provide the intended function under the expected condition.
  • stably interact is meant interaction of the small interfering RNA with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target xinder physiological conditions).
  • ribozymes can be expressed in a controlled manner in a subject for therapeutic purposes.
  • a ribozyme can be designed which discriminates between a mutated form of a gene and a wild-type gene.
  • a "correct" gene e.g., a wild-type p53 gene
  • a regulated ribozyme specific for the mutated form of the gene e.g., a mutated endogenous p53 gene
  • This approach is particularly advantageous in situations in which a gene product from the defective gene would interfere with the action of the exogenous wild-type gene.
  • the lentiviral vectors and lentiviral particles of the invention can be used to stimulate the expression of specific genes in animals to mimic the pathophysiology of human disease to thereby create animal models of human disease.
  • a gene of interest thought to be involved in a disease can be placed under the transcriptional control of one or more transcriptional regulatory sequence (e.g., by homologous recombination, as described herein).
  • Such an animal can be mated to a second animal carrying the transcriptional repressor under the control of the second promoter, to create progeny that carry both polynucleotides. Expression of the gene of interest in these progeny can be modulated using a tetracycline or analog thereof.
  • expression of the gene of interest can be down modulated using silencing molecules specific for the target gene under the control of the transcriptional regulatory sequence.
  • silencing molecules specific for the target gene under the control of the transcriptional regulatory sequence.
  • Such an approach may be advantageous over gene "knock out” by homologous recombination to create animal models of disease, since the regulated system described herein allows for control over both the levels of expression of the gene of interest and the timing of when gene expression is down- or up-regulated.
  • the methods of the invention can be employed in combination with invasive or more preferably, non-invasive imaging techniques, to monitor regulated gene expression in cells, cell lines and/or living subjects.
  • a reporter gene e.g., luciferase, GFP, CAT, etc.
  • a nucleotide sequence of interest may be placed under the control of a transcriptional regulatory sequence, thereby rendering expression of the reporter gene and nucleotide sequence of interest responsive to a ligand of the transcriptional repressor.
  • transgenic animals and cell lines may be derived within which expression and/or activity of a reporter gene such as luciferase serves as an indirect, non-invasive marker of the expression of the tet operator-linked nucleotide sequence.
  • a reporter gene such as luciferase serves as an indirect, non-invasive marker of the expression of the tet operator-linked nucleotide sequence.
  • reporter gene or “reporter gene” generically refers to an expressible (e.g., able to transcribed and (optionally) translated) DNA sequence which is expressed in response to the activity of a transcriptional regulatory protein.
  • Indicator genes include unmodified endogenous genes of the host cell, modified endogenous genes, or a reporter gene of a heterologous construct, e.g., as part of a reporter gene construct.
  • the level of expression of an indicator gene produces a detectable signal.
  • reporter genes include, but are not limited to CAT (chloramphenicol acetyl transferase) ( Alton and Napnek, 1979, Nature 282: 864-869 ) luciferase, and other enzyme detection systems, such as beta-galactosidase; firefly luciferase ( deWet et al. (1987), Mol. Cell Biol.
  • the indicator gene is green fluorescent protein ( U.S. patent 5,491,084 ; WO96/23898 ).
  • compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
  • Such compositions typically comprise the nucleic acid molecule and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absoftion delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
  • Supplementary active compounds can also be incorporated into the compositions.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • 293T cells (ATCC: CRL-11268) were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS, Invitrogen), 1% essential amino-acids and antibiotics.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS Fetal Bovine Serum
  • Human mesenchymal stem cells (hMSCs) were obtained from Inbiobank (www.inbiobank.org; San Diego, Spain), and were cultured in Advanced-DMEM (Gibco) plus 10% FBS. When cell cultures achieved over 85% of density, adherent cells were trypsinized, washed in PBS and replated at a concentration of 5 ⁇ 10 3 cells/cm 2 .
  • the StetR vector plasmid was obtained by replacing EGFP cDNA from the pHRSIN-CSEW ( Demaison et al., Hum Gene Ther 2002; 13: 803-13 ) plasmid (using BamHI and NotI excision) with a TetR cDNA obtained by PCR using pcDNA6TR (Invitrogene) as a template and the BamH1-tetR Fw (5' GGATCCATGTCTAGATTAGATAAAAG, SEQ ID NO: 18) and Not-TetR reverse (5' GCGGCCGCTTAATAAGATCTGAATTCCCGGG, SEQ ID NO:19). Primers to include the BamHI NotI sites at both ends.
  • CTetOE vector plasmid To construct the CTetOE vector plasmid, we used pHRSIN-CSEW vector as backbone, excising the SFFV promoter using EcoRI/BamHI restriction enzymes. A PCR fragment containing CMVTetO cassette was obtained by PCR using the EcoR1 forward (CCG GAATTC GTTGACATTGATTATTGACTA, SEQ ID NO:20) and BamH1 reverse (CGC GGATCC CGGAAGATGGATCGGTCC, SEQ ID NO:21) primers and the pcDNA4/TO plasmid (Invitrogene) as template.
  • EcoR1 forward CCG GAATTC GTTGACATTGATTATTGACTA, SEQ ID NO:20
  • BamH1 reverse CGC GGATCC CGGAAGATGGATCGGTCC, SEQ ID NO:21
  • All-in-one CEST lentiviral vector The CEST vector plasmid harboring the CMV-tetO regulatable cassette driving the expression of GFP as well as the spleen focus-forming virus promoter driving the expression of the TetR repressor gene was constructed by cloning the SFFV-TetR PstI fragment from the STetR vector into the unique Pst1 restriction site of the CTetOE vector.
  • HIV packing plasmid pCMVDR 8.9
  • VSG-G plasmid pMD.G
  • Vector production was performed as described previously ( Toscano et al., 2004, Gene Ther 2004; 11: 956-61 ).
  • the real time PCRs were performed using the QuantiTect TM SYBR Green PCR Kit (from Qiagen).
  • WPRE-F 5'-CACCACCTGTCAGCTCCTTT (SEQ ID NO: 22)
  • WPRE-R 5'-ACAACACCACGGAATTGTCA (SEQ ID NO: 23)
  • the parameters for the PCR were 1 ⁇ (95°C, 2 min); 40 ⁇ (95°C, 15 sec / 63°C, 30 sec / 72°C, 30 sec); 1 ⁇ (72°C 2 min).
  • Cytosolic and nuclear fraction of transduced cells were obtained using the Qproteome nuclear protein Kit (Qiagen) following manufacturer's instruction. Proteins were resolved by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE; 10% polyacrylamide gels, reducing conditions), and electrotransferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare Life Sciences, Buckinghamshire, UK).
  • SDS-PAGE sodium dodecyl sulfate- polyacrylamide gel electrophoresis
  • PVDF Hybond-P polyvinylidene difluoride
  • Membranes were blocked with 5% nonfat milk and probed for 1 hr at room temperature with rabbit anti-GRB2 (BD pharmingen; no 559266), rabbit anti-actin (Sigma; A5060) and mouse anti-Tet-repressor (Mobitec; TET02).
  • Combination of IRDye 680LT Goat anti-Rabbit IgG (Licors: 26-68021) and IRDye 800CW Goat anti-Mouse IgG (Licors: 926-32210) were use at 1:10.000 dilutions to analyzed TetR protein in combination with either actin or GRB2. After washing the membranes, detection and quantification of protein were performed using Odyssey Image Scanner System (Licor Biosciences, Cambridge, UK) using IRdye-conjugated secondary antibodies (Licor) and the Odyssey quantification software.
  • MSCs were collected, washed and pre-incubated in a PBS-blocking solution containing 3% of fetal bovine serum (FBS) and 0,2% sodium azide for 15 minutes at 4°C.
  • FBS fetal bovine serum
  • the following antibodies were used to fully characterize expression pattern of transduced and untransduced MSCs: anti human CD90-FITC, CD73-PE, CD105-FITC, CD166-PE, CD106-PE, CD45-PERCP, CD34-APC, HLA-DR-PERCP, CD19-APC all form Becton Dickinson (BD).
  • Antibodies were diluted in PBS 0,3% of FBS and 0,02% sodium azide.
  • Cells were incubated with 100 ⁇ l of the different antibodies (1/100), for 1h at 4°C and agitation and washed in PBS 0,3% of FBS and 0,02% sodium azide followed by a final wash in PBS alone. Cells were analyzed in FACScan Flow Cytometer.
  • Transduced cells incubated in the presence or absence of different concentrations of doxycyccline were analyzed by flow cytometry to determine the percentage of eGFP positive cells and the Mean fluorescence intensity (MFI) of either, the eGFP+ population or the entire population.
  • the Fold induction index was estimated as arbitrary units obtained by following formula: % eGFP + + Dox / % eGFP + ⁇ Dox ⁇ MFI eGFP + cells + Dox / MFI eGFP + cells ⁇
  • Dox Leakiness of the system was determined by using the following formula: % eGFP + ⁇ Dox / % eGFP + + Dox ⁇ MFI eGFP + cells ⁇ Dox
  • FIG. 1A Based on the two key expression vectors of the T-Rex Expression System (pcDNA4/TO-E and pcDNA/TR, Invitrogen), an alternative two lentiviral vector system based on pHRSIN-WPRE lentiviral vector was constructed ( Figure 1A ).
  • the first vector expresses the TetR repressor (STetR) through the SFFV promoter and the second expresses eGFP through the regulatable CMV-TetO promoter (CTetOE) (see M&M).
  • the titre obtained with the StetR vector was above 10.000.000tu/ml before concentration.
  • TetR-based system High Induction and low leakiness of the TetR-based system is dependent on high TetR concentration but independent on CMVTetO target sites.
  • Transactivator-containing repressor are quite toxic for most of the cells and must be kept at low concentration. In order to achieve good regulation, the concentration of TetO binding sites must be kept low to equal low repressor concentrations. It was therefore studied whether this was also the case for the unmodified TetR-based systems by using STetR and CTetOE lentiviral vectors. Increasing amounts of STetR were used to obtain 293T cell lines with increasing amounts of TetR repressor ( Figure 2A ; from left to right). All these 293T-TetR cell lines were transduced with increasing amounts of the CTetOE to obtain increasing concentrations of CMVTetO targets ( Figure 2A : from top to bottom).
  • MSCs are an important target for cell-gene therapy applications. Their role in regeneration, immunomodulation as well as their migratory capabilities to inflammatory locations makes them an attractive target for gene manipulation.
  • the development of an efficient doxycycline-responsive gene transfer system to achieve high levels of transgene expression in MSCs (without affecting its phenotype) is of special interest for the field.
  • the potential changes on doxycycline-responsive hMSCs compared with parental hMSCs were studied. No changes on either the expression of the main surface markers ( Figure 4A ) nor in the cell cycle cycle status ( Figure 4B ) could be detected.
  • the CEST vector is very efficient modulating transgene expression in immortalized cell lines and in highly permissive primary cells such as mesenchymal stem cells.
  • cells that are difficult to transduce such as the human embryonic stem cells (hESCs)
  • the vector is not able to block expression and has a strong leaking. The reason for this is the requirement of integrate 2-4 copies of CEST per cell in order to achieve the TetR concentrations necessary to stop gene expression.
  • the CEST vector was improved by:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Traffic Control Systems (AREA)

Claims (10)

  1. Ein lentiviraler Vektor, umfassend ein Polynukleotid, wobei das Polynukleotid umfasst
    (i) eine transkriptionelle regulatorische Sequenz, die einen ersten Promotor und mindestens eine Bindungsstelle für einen Transkriptionsrepressor umfasst, wobei der erste Promotor und die Bindungsstelle für einen Transkriptionsrepressor so angeordnet sind, dass die Bindung des Transkriptionsrepressor an die Bindungsstelle die transkriptionelle Aktivität des Promotors inhibiert und
    (ii) eine Expressionskassette, die ein Polynukleotid umfasst, das für einen regulierbaren Transkriptionsrepressor unter der operativen Kontrolle eines zweiten Promotors kodiert, wobei der regulierbare Transkriptionsrepressor in der Lage ist, spezifisch an die Bindungsstelle in der transkriptionellen regulatorischen Sequenz in Abwesenheit, aber nicht in Gegenwart eines Liganden davon zu binden,
    wobei der erste Promotor der sofortige frühe Promotor des Cytomegalovirus (CMV) ist, wobei die Bindungsstelle für den Transkriptionsrepressor eine TetO-Operatorsequenz umfasst, wobei der regulierbare Transkriptionsrepressor der Tetracyclin-Repressor ist und wobei der zweite Promotor aus der Gruppe ausgewählt ist, die aus dem Spleen Focus Forming Virus (SFFV) Long Term Repeat (LTR) Promotor und dem Elongationsfaktor lalpha (EF1α) Promotor besteht.
  2. Ein lentiviraler Vektor nach Anspruch 1, wobei die Bindungsstelle für den Transkriptionsrepressor stromabwärts des ersten Promotors liegt.
  3. Ein lentiviraler Vektor nach einem der Ansprüche 1 oder 2, wobei der regulierbare Transkriptionsrepressor ferner ein Kernlokalisierungssignal umfasst.
  4. Ein lentiviraler Vektor nach einem der Ansprüche 1 bis 3, der ferner ein Polynukleotid von Interesse unter operativer Kontrolle der transkriptionellen regulatorischen Sequenz umfasst.
  5. Ein lentivirales Partikel oder eine Wirtszelle, die einen lentiviralen Vektor nach einem der Ansprüche 1 bis 4 umfassen.
  6. Eine Zusammensetzung oder ein Kit-of-Parts, umfassend den lentiviralen Vektor nach einem der Ansprüche 1 bis 4 und einen Liganden des Transkriptionsrepressors, der, wenn er an den Repressor gebunden ist, zu einem inaktiven Repressor führt, der nicht mehr in der Lage ist, an seine Bindungsstelle in der transkriptionellen Regulationssequenz zu binden.
  7. Ein in vitro Verfahren zur Regulierung der Expression einer Nukleinsäuresequenz von Interesse, umfassend die Schritte
    (i) Bereitstellen einer Wirtszelle, die einen lentiviralen Vektor nach einem der Ansprüche 1 bis 4 umfasst, wobei die Nukleinsäure von Interesse operativ mit dem ersten Promotor in dem Polynukleotid verbunden ist, und
    (ii) Inkontaktbringen der Wirtszelle mit einem Liganden für den Transkriptionsrepressor, wobei der Ligand in der Lage ist, an den Transkriptionsrepressor zu binden, wodurch ein inaktiver Repressor erzeugt wird, der von seiner Bindungsstelle in der Transkriptionsregulationssequenz freigesetzt wird, wodurch die Transkription der durch den ersten Promotor angetriebenen Nukleinsäure ermöglicht wird.
  8. Ein Verfahren nach Anspruch 7, wobei die Zelle eine mesenchymale Stammzelle, vorzugsweise eine menschliche mesenchymale Stammzelle, ist.
  9. Ein lentiviraler Vektor nach einem der Ansprüche 1 bis 4 oder das lentivirale Partikel oder Wirtszellen nach Anspruch 5 zur Verwendung in der Medizin.
  10. Ein lentiviraler Vektor nach einem der Ansprüche 1 bis 4 oder ein lentivirales Partikel oder Wirtszelle nach Anspruch 5 zur Verwendung in der Behandlung einer Krankheit, die die Expression des Polynukleotids unter operativer Kontrolle der transkriptionellen Regulationssequenz erfordert.
EP12727326.6A 2011-05-19 2012-05-21 Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren Active EP2710130B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12727326.6A EP2710130B1 (de) 2011-05-19 2012-05-21 Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166754 2011-05-19
EP12727326.6A EP2710130B1 (de) 2011-05-19 2012-05-21 Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren
PCT/EP2012/059408 WO2012156535A1 (en) 2011-05-19 2012-05-21 Highly inducible dual-promoter lentiviral tet-on system

Publications (2)

Publication Number Publication Date
EP2710130A1 EP2710130A1 (de) 2014-03-26
EP2710130B1 true EP2710130B1 (de) 2022-06-29

Family

ID=46275792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12727326.6A Active EP2710130B1 (de) 2011-05-19 2012-05-21 Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren

Country Status (4)

Country Link
US (2) US9822379B2 (de)
EP (1) EP2710130B1 (de)
ES (1) ES2931180T3 (de)
WO (1) WO2012156535A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
CN105734138B (zh) * 2015-12-16 2021-05-07 云南农业大学 基于四环素调控系统检测叶绿体启动子活性的方法
CA3030340A1 (en) 2016-08-01 2018-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
WO2018083274A1 (en) * 2016-11-04 2018-05-11 Fundación Pública Andaluza Progreso Y Salud Lent-on-plus system for conditional expression in human stem cells
CA3051442A1 (en) 2017-02-14 2018-08-23 Alejandro Soto-Gutierrez Methods of engineering human induced pluripotent stem cells to produce liver tissue
EP3758736B1 (de) 2018-03-02 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Il-34 zur anwendung in einem verfahren zur behandlung von retinaler entzündung und neurodegeneration
CN113164625A (zh) * 2018-09-28 2021-07-23 哈佛大学的校长及成员们 用于基因表达的突变体反向四环素反式激活因子
CN109913424B (zh) * 2019-03-28 2020-10-27 浙江大学 一种包含戊型肝炎病毒复制子的人肝癌细胞系、应用及构建方法
CA3136574A1 (en) * 2019-05-10 2020-11-19 Jung Joon Min Dna construct for diagnosing and treating cancer
EP4208553A1 (de) * 2020-09-02 2023-07-12 University of Utah Research Foundation Systeme und verfahren zur steuerung bakterieller transkription
CN114134251A (zh) * 2020-09-04 2022-03-04 西比曼生物科技（香港）有限公司 一种快速检测慢病毒载体滴度的方法
KR102632204B1 (ko) * 2022-03-24 2024-02-02 (주)셀레브레인 신규 재조합 벡터 및 이의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE48617T1 (de) 1984-04-13 1989-12-15 Litton Bionetics Inc Leukoregulin, ein antitumor-lymphokin und dessen verwendung als heilmittel.
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
EP0705334A1 (de) 1993-06-14 1996-04-10 Basf Aktiengesellschaft Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE69618350T2 (de) 1995-01-31 2002-09-19 Bioimage As Soeborg Ein verfahren zum nachweis biologisch aktiver substanzen
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ATE458818T1 (de) 1999-06-07 2010-03-15 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
CA2652346A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
KR100952659B1 (ko) 2007-08-23 2010-04-13 한양대학교 산학협력단 테트라사이클린-조절 시스템에 의해 유전자 과발현 및 발현감소를 동시에 유도할 수 있는 렌티바이러스 벡터
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAO ET AL: "Highly Efficient Regulation of Gene Expression by Tetracycline in a Replication-Defective Herpes Simplex Viral Vector", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, CELL PRESS, US, vol. 13, no. 6, 1 June 2006 (2006-06-01), pages 1133 - 1141, XP005469387, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2006.01.009 *

Also Published As

Publication number Publication date
US20180066284A1 (en) 2018-03-08
ES2931180T3 (es) 2022-12-27
WO2012156535A1 (en) 2012-11-22
EP2710130A1 (de) 2014-03-26
US9822379B2 (en) 2017-11-21
US20140107190A1 (en) 2014-04-17
US10590434B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
EP2710130B1 (de) Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren
US10876133B2 (en) Method for expression of small RNA molecules within a cell
Lee et al. Regulation of the Th2 cytokine locus by a locus control region
JP4024830B2 (ja) Ｈｈｖ−７由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法
US5919667A (en) Modular assembly retroviral vectors and uses thereof
EP2166107A1 (de) Lentivirale Vektoren zur Expression von shRNA
JP2005512598A (ja) Ｅｉａｖなどのレンチウイルス発現ベクターを使用するトランスジェニック生物の作製方法
US20040234504A1 (en) Methods of inhibiting gene expression by RNA interference
JP2002507895A (ja) 段階的なトランス活性化能を有する転写活性化因子
JP2024041866A (ja) 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
US20210222199A1 (en) Adeno-associated viral vector, compositions, methods of promoting muscle regeneration, and treatment methods
US20150376627A1 (en) Inducible Expression System Transcription Modulators Comprising A Distributed Protein Transduction Domain And Methods For Using The Same
US20080312171A1 (en) Tetracycline-Dependent Regulation of Rna Interference
CN110551753B (zh) 构建强力霉素/米非司酮诱导过表达的带有荧光蛋白标记基因的双诱导表达载体
Romeo et al. AAV diffuses across zona pellucida for effortless gene delivery to fertilized eggs
WO1997048277A1 (en) Modular assembly retroviral vectors and uses thereof
WO1997048277A9 (en) Modular assembly retroviral vectors and uses thereof
Kiyosue et al. Epstein-Barr virus-derived vector suitable for long-term expression in neurons
CN109504679A (zh) 用于基因在禽类骨骼肌中特异性表达的启动子以及应用
KR20220004973A (ko) 보체-매개 용해에 대한 세포 감수성을 증가시키는 방법
US20080153764A1 (en) System and Methods For Short Rna Expression
Stacey Investigating the Mechanism of Establishment of a Prototype Episomal Gene Therapy Vector
Zhou Transcriptional Regulation of the murine testis-specific lactate dehydrogenase c gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUTO DE SALUD CARLOS III

Owner name: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

17Q First examination report despatched

Effective date: 20160615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20210820BHEP

Ipc: C12N 15/867 20060101ALI20210820BHEP

Ipc: C12N 15/85 20060101AFI20210820BHEP

INTG Intention to grant announced

Effective date: 20210928

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20220218

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1501383

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012078425

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220929

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220930

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220929

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220629

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1501383

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2931180

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221031

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221029

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012078425

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230330

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230525

Year of fee payment: 12

Ref country code: ES

Payment date: 20230621

Year of fee payment: 12

Ref country code: DE

Payment date: 20230530

Year of fee payment: 12

Ref country code: CH

Payment date: 20230610

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230529

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230529

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230521

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230521